|
1
|
Rodriguez A, Griffiths-Jones S, Ashurst JL
and Bradley A: Identification of mammalian microRNA host genes and
transcription units. Genome Res. 14:1902–1910. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Farazi TA, Spitzer JI, Morozov and Tuschl
T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynam-Lennon N, Maher SG and Reynolds JV:
The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos
Soc. 84:55–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delgado J and Villamor N: Chronic
lymphocytic leukemia in young individuals revisited. Haematologica.
99:4–5. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bacher U, Kern W, Schoch C, Hiddemann W
and Haferlach T: Discrimination of chronic lymphocytic leukemia
(CLL) and CLL/PL by cytomorphology can clearly be correlated to
specific genetic markers as investigated by interphase fluorescence
in situ hybridization (FISH). Ann Hematol. 83:349–355. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dal Bo M, Rossi FM, Rossi D, Deambrogi C,
Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, et
al: 13q14 deletion size and number of deleted cells both influence
prognosis in chronic lymphocytic leukemia. Genes Chromosomes
Cancer. 50:633–643. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Klein U, Lia M, Crespo M, Siegel R, Shen
Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G and
Dalla-Favera R: The DLEU2/miR-15a/16-1 cluster controls B cell
proliferation and its deletion leads to chronic lymphocytic
leukemia. Cancer Cell. 17:28–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palamarchuk A, Efanov A, Nazaryan N,
Santanam U, Alder H, Rassenti L, Kipps T, Croce CM and Pekarsky Y:
13q14 deletions in CLL involve cooperating tumor suppressors.
Blood. 115:3916–3922. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kiefer Y, Schulte C, Tiemann M and
Bullerdiek J: Chronic lymphocytic leukemia-associated chromosomal
abnormalities and miRNA deregulation. The Application of Clinical
Genetics. 5:21–28. 2012.PubMed/NCBI
|
|
10
|
Austen B, Powell JE, Alvi A, Edwards I,
Hooper L, Starczynski J, Taylor AM, Fegan C, Moss P and Stankovic
T: Mutations in the ATM gene lead to impaired overall and
treatment-free survival that is independent of IGVH mutation status
in patients with B-CLL. Blood. 106:3175–3182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Döhner H, Stilgenbauer S, Benner A,
Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M and Lichter P:
Genomic aberrations and survival in chronic lymphocytic leukemia. N
Engl J Med. 343:1910–1916. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Döhner H, Stilgenbauer S, James MR, Benner
A, Weilguni T, Bentz M, Fischer K, Hunstein W and Lichter P: 11q
deletions identify a new subset of B-cell chronic lymphocytic
leukemia characterized by extensive nodal involvement and inferior
prognosis. Blood. 89:2516–2522. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marasca R, Maffei R, Martinelli S,
Fiorcari S, Bulgarelli J, Debbia G, Rossi D, Rossi FM, Rigolin GM,
Martinelli S, et al: Clinical heterogeneity of de novo 11q deletion
chronic lymphocytic leukaemia: Prognostic relevance of extent of
11q deleted nuclei inside leukemic clone. Hematol Oncol. 31:88–95.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matutes E, Oscier D, Garcia-Marco J, Ellis
J, Copplestone A, Gillingham R, Hamblin T, Lens D, Swansbury GJ and
Catovsky D: Trisomy 12 defines a group of CLL with atypical
morphology: Correlation between cytogenetic, clinical and
laboratory features in 544 patients. Br J Haematol. 92:382–388.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zent CS, Kyasa MJ, Evans R and Schichman
SA: Chronic lymphocytic leukemia incidence is substantially higher
than estimated from tumor registry data. Cancer. 92:1325–1330.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zenz T, Eichhorst B, Busch R, Denzel T,
Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G,
et al: TP53 mutation and survival in chronic lymphocytic leukemia.
J Clin Oncol. 28:4473–4479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bullrich F, Fujii H, Calin G, Mabuchi H,
Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, et
al: Characterization of the 13q14 tumor suppressor locus in CLL:
Identification of ALT1, an alternative splice variant of the LEU2
gene. Cancer Res. 61:6640–6648. 2001.PubMed/NCBI
|
|
18
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pekarsky Y, Santanam U, Cimmino A,
Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG,
Rassenti L, et al: Tcl1 expression in chronic lymphocytic leukemia
is regulated by miR-29 and miR-181. Cancer Res. 66:11590–11593.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zenz T, Häbe S, Denzel T, Mohr J, Winkler
D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, et al: Detailed
analysis of p53 pathway defects in fludarabine-refractory chronic
lymphocytic leukemia (CLL): Dissecting the contribution of 17p
deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a
prospective clinical trial. Blood. 114:2589–2597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Calin GA, Liu CG, Sevignani C, Ferracin M,
Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al:
MicroRNA profiling reveals distinct signaturesin B cell chronic
lymphocytic leukemias. Proc Natl Acad Sci USA. 101:11755–11760.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sandhu SK, Volinia S, Costinean S, Galasso
M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G,
Garzon R and Croce CM: miR-155 targets histone deacetylase 4
(HDAC4) and impairs transcriptional activity of B-cell lymphoma 6
(BCL6) in the Eµ-miR-155 transgenic mouse model. Proc Natl Acad Sci
USA. 109:20047–2052. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Frenquelli M, Muzio M, Scielzo C, Fazi C,
Scarfò L, Rossi C, Ferrari G, Ghia P and Caligaris-Cappio F:
MicroRNA and proliferation control in chronic lymphocytic leukemia:
Functional relationship between miR-221/222 cluster and p27. Blood.
115:3949–3959. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Montillo M, Hamblin T, Hallek M,
Montserrat E and Morra E: Chronic lymphocytic leukemia: Novel
prognostic factors and their relevance for risk-adapted therapeutic
strategies. Haematologica. 90:391–399. 2005.PubMed/NCBI
|
|
25
|
Hallek M, Cheson BD, Catovsky D,
Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ,
Montserrat E, Rai KR, et al: Guidelines for the diagnosis and
treatment of chronic lymphocytic leukemia: A report from the
International Workshop on Chronic Lymphocytic Leukemia updating the
National Cancer Institute-Working Group 1996 guidelines. Blood.
111:5446–5456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mato A, Nabhan C, Kay NE, Lamanna N, Kipps
TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, et
al: Prognostic Testing patterns and outcomes of chronic lymphocytic
leukemia patients stratified by fluorescence in situ
hybridization/cytogenetics: A real-world clinical experience in the
connect CLL registry. Clin Lymphoma Myeloma Leuk. 18:114–124.e2.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hallek M, Cheson BD, Catovsky D,
Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M,
Montserrat E, Chiorazzi N, et al: iwCLL guidelines for diagnosis,
indications for treatment, response assessment, and supportive
management of CLL. Blood. 131:2745–2760. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eichhorst B, Robak T, Montserrat E, Ghia
P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen
P, et al: Chronic lymphocytic leukaemia: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
32:23–33. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baliakas P, Jeromin S, Iskas M, Puiggros
A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A,
Xochelli A, et al: Cytogenetic complexity in chronic lymphocytic
leukemia: Definitions, associations, and clinical impact. Blood.
133:1205–1216. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Galka-Marciniak P, Urbanek-Trzeciak MO,
Nawrocka PM, Dutkiewicz A, Giefing M, Lewandowska MA and Kozlowski
P: Somatic mutations in miRNA genes in lung cancer-potential
functional consequences of non-coding sequence variants. Cancers
(Basel). 11:7932019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao Y, Lin L, Li T, Yang J and Wei Y: The
role of miRNA-223 in cancer: Function, diagnosis and therapy. Gene.
616:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo P, Wang Q, Ye Y, Zhang J, Lu D, Cheng
L, Zhou H, Xie M and Wang B: miR-223-3p functions as a tumor
suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53
regulatory feedback loop. J Exp Clin Cancer Res. 38:742019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Humplikova L, Kollinerova S, Papajik T,
Pikalova Z, Holzerova M, Prochazka V, Divoka M, Modriansky M,
Indrak K and Jarosova M: Expression of miR-15a and miR-16-1 in
patients with chronic lymphocytic leukemia. Biomed Pap Med Fac Univ
Palacky Olomouc Czech Repub. 157:284–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rossi M, Fuligni F, Ciccone M, Agostinelli
C, Righi S, Luciani M, Laginestra MA, Rigolin GM, Sapienza MR,
Gazzola A, et al: Hsa-miR-15a and Hsa-miR-16-1 expression is not
related to proliferation centers abundance and other prognostic
factors in chronic lymphocytic leukemia. Biomed Res Int.
2013:7153912013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang
YH, Liu P, Hong M, Miao KR, Liu P, et al: miR-181a/b significantly
enhances drug sensitivity in chronic lymphocytic leukemia cells via
targeting multiple anti-apoptosis genes. Carcinogenesis.
33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Visone R, Veronese A, Balatti V and Croce
CM: miR-181b: New perspective to evaluate disease progression in
chronic lymphocytic leukemia. Oncotarget. 3:195–202. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Visone R, Veronese A, Rassenti LZ, Balatti
V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ and Croce
CM: miR-181b is a biomarker of disease progression in chronic
lymphocytic leukemia. Blood. 118:3072–3079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou K, Yi S, Yu Z, Li Z, Wang Y, Zou D,
Qi J, Zhao Y and Qiu L: MicroRNA-223 expression is uniformly
down-regulated in B cell lymphoproliferative disorders and is
associated with poor survival in patients with chronic lymphocytic
leukemia. Leuk Lymphoma. 53:1155–1161. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang L, Zhao W, Wei P, Zuo W and Zhu S:
Tumor suppressor p53 induces miR-15a processing to inhibit neuronal
apoptosis inhibitory protein (NAIP) in the apoptotic response DNA
damage in breast cancer cell. Am J Transl Res. 9:683–691.
2017.PubMed/NCBI
|
|
41
|
Fabbri M, Bottoni A, Shimizu M, Spizzo R,
Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE,
et al: Association of a microRNA/TP53 feedback circuitry with
pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
JAMA. 305:59–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu J, Chen G, Feng L, Zhang W, Pelicano
H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, et al: Loss of
p53 and altered miR15-a/16-1 MCL-1 pathway in CLL: Insights from
TCL1-Tg:p53(−/−) mouse model and primary human leukemia cells.
Leukemia. 28:118–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Janaki RM: Functions and epigenetic
aspects of miR-15/16: Possible future cancer therapeutics. Gene
Reports. 12:149–164. 2018. View Article : Google Scholar
|
|
44
|
Pekarsky Y and Croce CM: Is miR-29 an
oncogene or tumor suppressor in CLL? Oncotarget. 1:224–227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mraz M, Malinova K, Kotaskova J, Pavlova
S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y,
Doubek M, et al: miR-34a, miR-29c and miR-17-5p are downregulated
in CLL patients with TP53 abnormalities. Leukemia. 23:1159–1163.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang L, Liao Y and Tang L: MicroRNA-34
family: a potential tumor suppressor and therapeutic candidate in
cancer. J Exp Clin Cancer Res. 38:532019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Balatti V, Pekarky Y, Rizzotto L and Croce
CM: miR deregulation in CLL. Advances in experimental medicine and
biology. 792:309–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Deneberg S, Kanduri M, Ali D, Bengtzen S,
Karimi M, Qu Y, Kimby E, Mansouri L, Rosenquist R, Lennartsson A
and Lehmann S: microRNA-34b/c on chromosome 11q23 is aberrantly
methylated in chronic lymphocytic leukemia. Epigenetics. 9:910–917.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Farahat NMG, Elkaffash DMNED, Alghandour
AH, Swelem RS and Abo El-Wafa RAH: Study of microRNA profile as a
molecular biomarker in Egyptian Chronic Lymphocytic Leukemia.
Indian J Hematol Blood Transfus. 35:89–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kaur G, Ruhela V, Rani L, Gupta A, Sriram
K, Gogia A, Sharma A, Kumar L and Gupta R: RNA-Seq profiling of
deregulated miRs in CLL and their impact on clinical outcome. Blood
Cancer J. 10:62020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fu Y, Chen J and Huang Z: Recent progress
in microRNA-based delivery systems for the treatment of human
disease. ExRNA. 1:242019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chakraborty C, Sharma AR, Sharma G and Lee
SS: Therapeutic advances of miRNAs: A preclinical and clinical
update. J Adv Res. 28:127–138. 2020. View Article : Google Scholar : PubMed/NCBI
|
